Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 14/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15333581 | 0.80 | POLB (0.43) | PDE2AKDRACVR2ATGFBR1TGFBR2 | |
| SCHEMBL15333599 | 0.77 | LPL (0.32) | PDE2AACVR2ATGFBR1TGFBR2 | |
| SCHEMBL15341776 | 0.77 | PDE2A (0.34) | PDE2AACVR2ATGFBR1TGFBR2 | |
| SCHEMBL15308505 | 0.76 | PDE2A (0.41) | PDE2APDE10APDE3AHSD11B1KDR | |
| SCHEMBL10258993 | 0.76 | KDM4E (0.40) | HSD11B1 | |
| SCHEMBL15344912 | 0.76 | CYP2A6 (0.46) | KDRACVR2ATGFBR1TGFBR2 | |
| SCHEMBL12517707 | 0.73 | PRKAB2 (0.51) | PDE2APDE10APDE3AHSD11B1KDR | |
| SCHEMBL21893829 | 0.73 | SMPD3 (0.48) | PDE2AHSD11B1KDR | |
| SCHEMBL16628978 | 0.73 | PDE2A (0.40) | PDE2APDE10APDE3AHSD11B1KDR | |
| SCHEMBL310126 | 0.73 | PDE2A (0.59) | PDE2APDE10APDE3AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020065614-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | PDE2A 1575/4885PDE10A 1377/4885PDE3A 1251/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | PDE2A 1575/4885PDE10A 1377/4885PDE3A 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.